#275 - AMA #52: Hormone replacement therapy: practical applications and the role of compounding pharmacies
Peter Attia, MD, and Nick Stenson discuss practical HRT/TRT for women, covering menopause diagnosis via FSH/AMH, perimenopausal symptoms, and the vital role of compounding pharmacies. This AMA aims to help listeners apply theoretical knowledge.
Deep Dive Analysis
7 Topic Outline
Introduction to Women's HRT and TRT
Importance of Re-examining Female Hormone Replacement Therapy
Misinterpretation of the Women's Health Initiative (WHI)
Clinical and Blood Tests for Menopause Diagnosis
Follicle Stimulating Hormone (FSH) as a Key Menopause Indicator
Anti-Müllerian Hormone (AMH) and Ovarian Reserve
Hormonal Changes Causing Vasomotor Symptoms
5 Key Concepts
Menopause
Menopause is a clinical diagnosis made retrospectively, requiring 12 consecutive months of not having a menstrual period without any other obvious pathological or physiological cause. Symptoms can precede this formal diagnosis, indicating perimenopause.
Follicle Stimulating Hormone (FSH)
FSH is a crucial hormone for assessing a woman's trajectory towards menopause. As a woman approaches menopause, FSH levels typically rise significantly, making it a key indicator when measured, especially on day five of a menstrual cycle.
Luteinizing Hormone (LH)
LH is another hormone, often measured alongside FSH, that indicates a woman's progression towards menopause. Its levels also tend to increase as ovarian function declines.
Anti-Müllerian Hormone (AMH)
AMH is a hormone produced by the granulosa cells of growing follicles, serving as a marker for ovarian reserve. Its levels decline precipitously before menopause, making it a useful tool for predicting fertility windows, though not typically used in Peter's practice for menopause prediction.
Vasomotor Symptoms
These are common menopausal symptoms, primarily hot flashes and night sweats. They tend to significantly precede other symptoms associated with menopause, such as vaginal dryness, vaginal atrophy, or loss of bone mineral density.
5 Questions Answered
Peter Attia believes the mainstream medical community misinterpreted the Women's Health Initiative, leading to a 'gross injustice' and demonization of hormones, which has harmed many women and compromised their quality of life without saving lives from breast cancer.
Menopause is technically diagnosed retrospectively, requiring 12 consecutive months of amenorrhea (not having a period) without any other clear pathological or physiological cause.
Measuring Follicle Stimulating Hormone (FSH) is the most important, along with Luteinizing Hormone (LH) and estradiol, typically on day five of a menstrual cycle if the woman is still having one.
AMH indicates ovarian reserve, with levels declining sharply before menopause; it's useful for assessing fertility potential, especially if reproduction is still being considered, but not typically used in Peter's practice for predicting menopause directly.
The most common early symptoms are vasomotor symptoms, such as hot flashes and night sweats, which tend to significantly precede other issues like vaginal dryness or loss of bone mineral density.
10 Actionable Insights
1. Seek Professional Medical Advice
Always seek assistance from healthcare professionals for any medical conditions, as this podcast is for general informational purposes only and not a substitute for professional medical advice, diagnosis, or treatment.
2. Men: Pay Attention to Women’s HRT
Men should pay close attention to discussions about women’s hormone replacement therapy, as the underlying principles are applicable to male hormones and can help them understand and support women in their lives.
3. Track Menopause with Blood Tests
To get a sense of a woman’s trajectory towards menopause, measure follicle-stimulating hormone (FSH) and, to a lesser extent, luteinizing hormone (LH) via blood tests.
4. Optimal Hormone Test Timing
For women still having a period, the gold standard is to measure FSH, LH, and estradiol on day five of the menstrual cycle, with day one being the day the period begins.
5. Predict Menopause with AMH
If a woman is over 40 and her Anti-Müllerian Hormone (AMH) level is below 0.2, there is a very high probability she will go through menopause in the next five years.
6. AMH for Perimenopause Status
If a woman’s AMH is above 1.5, even if she is over 40, she is likely not perimenopausal, and menopause is probably at least six years away.
7. Understand Menopause Diagnosis
Menopause is clinically diagnosed retrospectively, requiring 12 months of amenorrhea (not having a period) without any other obvious pathologic or physiologic cause.
8. Leverage Premium Membership Benefits
Premium membership includes comprehensive show notes, monthly AMA episodes, a premium newsletter, access to a private podcast feed, and ‘The Qualies’ podcast featuring episode highlights.
9. Watch Female Hormone Video
Watch the video on female reproductive hormone systems (linked in the show notes) to understand what FSH and LH are doing and how they change throughout a cycle.
10. Watch Podcast Video
Subscribers can watch the full video of this podcast on the show notes page, and non-subscribers can watch a sneak peek of the video on the YouTube page.
3 Key Quotes
I still believe the sort of mainstream medical community has committed a gross injustice over the past 20 years in the misinterpretation of the women's health initiative and the subsequent demonization of hormones in perimenopausal and postmenopausal therapy for women.
Peter Attia
The sum total of lives that have been saved due to less breast cancer as a result from the lack of hrt over the past 20 years is exactly zero.
Peter Attia
Menopause is a clinical diagnosis and technically it's really diagnosed retrospectively, it requires 12 months of amenorrhea so 12 months of not having a period without any other obvious pathologic or physiologic cause.
Peter Attia